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Targeted alpha therapy (TAT) has the advantage of delivering therapeutic doses to individual cancer cells while reducing the dose
to normal tissues. TAT applications relate to hematologic malignancies and now extend to solid tumors. Results from several
clinical trials have shown efficacy with limited toxicity. However, the dosimetry for the labeled alpha particle is challenging because
of the heterogeneous antigen expression among cancer cells and the nature of short-range, high-LET alpha radiation. This paper
demonstrates that it is inappropriate to investigate the therapeutic efficacy of TAT by macrodosimetry. The objective of this work is
to review the microdosimetry of TAT as a function of the cell geometry, source-target configuration, cell sensitivity, and biological
factors. A detailed knowledge of each of these parameters is required for accurate microdosimetric calculations.
1. Introduction
Targeted alpha therapy (TAT) can provide selective systemic
radiotherapy to primary and metastatic tumors (even at a
low dose rate and hypoxia region) [1]. It permits sensitive
discrimination between target and normal tissue, resulting in
fewer toxic side effects than most conventional chemothera-
peutic drugs. Monoclonal antibodies (MAbs) that recognize
tumor-associated antigens are conjugated to potent alpha
emitting radionuclides to form the alpha-immunoconjugate
(AIC) (Figure 1). The AIC can be administered by intra-
lesional, orthotopic, or systemic injection. Targeted cancer
cells are killed by the short-range alpha radiation, while spar-
ing distant normal tissue cells, giving the minimal toxicity to
normal tissue [2].
An alpha particle with energy of 4 to 9 MeV can deposit
about 100 keV/μm within a few cell diameters (40–90 μm),
causing direct DNA double-strand breaks, which lead to
cancer cell apoptosis [3]. Cell survival is relatively insensitive
to the cell cycle or oxygen status for alpha radiation [4]. TAT
is potent enough to eradicate disseminated cancer cells or
cancer stem cells that are minimally susceptible to chemo- or
radio-resistance. The relative biological effect (RBE) of alpha
particles is from 3 to 7 [5], which means that for the same
absorbed dose, the acute biological effects of alpha particles
are 3 to 7 times greater than the damage caused by external
beam photons or beta radiation.
TAT is ideally suited to liquid cancers or micrometastases
[6]. However the regression of metastatic melanoma lesions
after systemic TAT in a phase I clinical trial for metastatic
melanoma has broadened the application to solid tumors [7].
The observed tumor regression could not be ascribed to kill-
ing of all cancer cells in the tumors by TAT and led to
the hypothesis that tumors could be regressed by a mecha-
nism called tumor antivascular alpha therapy (TAVAT) [8].
Therapeutic efficacy relates to the extravasation of the AIC
through porous tumor vascular walls and widened endo-
thelial junctions into the perivascular space in the solid
tumor. The AICs bind to antigenic sites on the membranes
of pericytes and contiguous cancer cells around the capillary.
The alpha-particle emitters are localized close to the vascular
endothelial cells (ECs), which are irradiated by alpha parti-
cles and killed. Subsequent tumor capillary closure, causing
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Figure 1: Schematic diagram of an AIC targeting a cell.
depletion of oxygen and nutrition, is the likely cause of can-
cer cell death and tumor regression [8, 9].
2. Microdosimetry
2.1. Microdosimetry Concept. Radiation dosimetry is the
study of the physical properties of radiation energy deposi-
tion in tissue. It can be used to optimize treatments and allow
comparison of different therapeutic approaches, as well as to
study the basic methods of irradiation of biological matter
[10]. Radiation dose in conventional external radiotherapy
is a macroscopic concept. Upon the properties of the short
path length alpha emissions and the spatial distribution of
the radionuclide relative to the small target volumes, micro-
dosimetry is indispensible for TAT to investigate the physical
properties of radiation energy deposition in biological cells
[11].
The dosimetry of TAT is distinguished from that of beta
immunotherapy [12] or external beam radiotherapy in three
different ways.
(1) Short path length of alpha particles. The high energy
of alpha particles is deposited in a short range [13].
Some cell nuclei receive multiple alpha particle hits,
while others receive no hits. The amounts of energy
deposited vary greatly from target to target, leading
to a wide frequency distribution [14].
(2) Small target volume. The alpha track length is com-
parable to cellular/subcellular sizes causing high LET
within the small target volume. It is important to
understand the differing biological effects on indi-
vidual cells [15]. Given the energy delivered along an
alpha-particle track and its potential cytotoxicity, the
dosimetry for estimating mean absorbed dose may
not always yield physically or biologically meaningful
information of radiation energy deposition in bio-
logical cells. Instead, stochastic or microdosimetric
methodologies may be required [16].
(3) Nonuniform distribution of radioisotopes. The hetero-
geneous antigen expression and tumor uptake leads
to variable spatial microdosimetric distributions of
the AIC [17]. Spatial and temporal changes of the
source activity in the target can also occur [4]. When
the distribution of radio-labeled antibody is nonuni-
form, techniques of dose averaging over volumes
greater in size than the individual target volumes can
become inadequate predictors of the biological effect
[18].
The specific energy is the most important quantity for micro-
dosimetry as it can be used to calculate the cancer cell sur-
vival rate. Specific energy (z Gy) is the ratio of the energy
deposited (ε Joule) to the mass of the target (m kg) (1) and
has the same units as absorbed dose [19]. The mean specific
energy equals the absorbed dose [15]. Although microdosi-
metry is concerned with the same concept of energy depo-
sition per unit mass as dosimetry, the difference in the length
of alpha particle and small size of the target volume intro-
duces stochastic effects which are negligible in conventional
dosimetry [20].
z = ε
m
Gy. (1)
The stochastic quantity of specific energy z can be used to
investigate biological effects [21]. The cell survival fraction
(SF) is given by
SF = e−z/z0 , (2)
where z0 is the absorbed dose required to reduce cell survival
to 37% [22].
Many microdosimetric models have been developed
since Roesch’s initial work [23]. Two different microdosimet-
ric methods can be used. Experimental measurement with
high-resolution solid-state microdosimeters is one way. The
high spatial resolution and the tissue-equivalence correction
detectors have been applied for hadron therapy and Boron
neutron capture therapy [24–26]. On the other hand, dose
distributions can be calculated with analytical calculations
[15] or Monte Carlo techniques based on fundamental phy-
sical principles [27]. The latter method is more practical and
much less expensive [19].
2.2. Microdosimetry Case Study. It is inappropriate to evalu-
ate the background dose for radioimmunotherapy, especially
for TAT by conventional dosimetry. For example, in the phase
I clinical trial for metastatic melanoma, patients received
up to 25 mCi of 213Bi [7]. Assuming that all the activity
injected in patient remains in the blood, 25 mCi corresponds
to 3.65 × 1012 213Bi atoms in the macrodosimetry point of
view. Taking the average energy of 8.32 MeV, the total energy
lost would be 4.8 Joules. The absorbed dose (z) received by
blood (5 L) would be calculated by
z = ε
m
= 4.8 J
5 kg
≈ 1 Gy. (3)
The above dosimetry would indicate that the blood system
would receive an absorbed dose of ∼1 Gy from alpha particle
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Table 1: Experimental values of z0 for in vitro exposure to alpha
radiation.
Cell line AIC z0 (Gy) Reference
MCF7 225Ac-Herceptin 0.27 [47]
BT 225Ac-Herceptin 0.37 [47]
MDA 225Ac-Herceptin 0.53 [47]
Line 1 213Bi-13A 1.4 [36]
EMT-6 213Bi-13A 1.7 [36]
irradiation. The risk for unwanted radiation exposures of
normal tissues would be too high.
However, by using Geant4 Monte Carlo microdosimetry
calculation, the actual dose to endothelial cells is ∼2 cGy
and to lymphocyte is ∼10 cGy [28], being 2% and 10% of
the macroscopic absorbed dose, respectively, and is too low
to post any serious damage. In other words, unless alphas
actually hit their target, their energy is lost to the medium
and has no effect on normal tissue.
Memorial Sloan Kettering found that the maximum tol-
erance dose was in excess of 1 mCi/kg for bone marrow
toxicity [29]. In the melanoma clinical trial [4], 25 mCi con-
verts to ∼0.3 mCi/kg and is well below that value. Thus, the
clinical trial result is consistent with the Monte Carlo cal-
culations. The entirely different result from two dosimetry
methods shows it is essential to use microdosimetry method
for TAT.
3. Factors Affecting TAT Microdosimetry Result
3.1. The Choice of the Target. Microdosimetry depends on
the choice of target, for example, the entire cell, cell nucleus,
or DNA. This is because the size of the target will affect both
the energy deposition and the mass which determines the
specific energy.
As has been substantiated by in vitro and in vivo experi-
ments, the radiosensitive sites are associated with DNA in the
cell nucleus. Microdosimetry research target has fluctuated
between DNA and cell nucleus. For alpha particles with a
range of a few cell diameters, the cell nucleus is an appro-
priate choice for the target considering the genome is
assumed to be randomly distributed throughout the cell
nucleus, and its specific location is not well known [20].
However, under the circumstances that if the particle (e.g.,
Auger electrons) range is a few μm and the source decays
within 1 or 2 nm of the DNA molecule, radiation dose to the
cell nucleus may be inadequate to predict radiation toxicity,
and determination of the energy deposition to the DNA
molecule may be necessary [30].
3.2. Target and Source Configuration. The TAT microdosime-
try dose is highly sensitive to experimental factors such as the
nucleus size and source distribution, kinetics of the AIC, and
subcellular distribution of the radionuclide.
Because of the short range of alpha particles, even small
changes in the thickness or diameter of the cell nucleus can
influence the dose distribution. Simplified spheroid models
with different cell and nucleus radii are used to model
cells [4, 15, 31]. Recently some more realistic models with
geometric parameters taken from monolayer or suspended
cells measurement were built [32–35].
The position of the source relative to the target cell
nucleus is another major factor in determining the hit pro-
bability, specific energy, and ultimately the efficacy of TAT
[36]. For a spherical single-cell model, the specific energy
from activity internalized in the cell nucleus, in the cyto-
plasm, on the cell membrane, or in the medium can differ
as much as 150 times [37]. Rapidly internalized antibodies or
radioisotopes are superior because of markedly greater intra-
cellular retention and higher probability of hit. However,
caution is needed as some animal studies indicate that the
retention of 111In and 90Y is prolonged in normal organs such
as bone, liver, and kidney as well [38].
3.3. Cell Sensitivity. The z0 value is highly sensitive to
experimental factors such as the distribution of DNA within
the nucleus (i.e., the phase of the cell cycle) and the number
and spatial distribution of the alpha particle sources relative
to the target cell nucleus [39]. It is also expected that the in
vitro cell sensitivity will vary between different cells within a
given tumor. Table 1 shows a survey of TAT in vitro experi-
ments, which illustrated that z0 values for cancer cell lines
exposed to alpha radiation can vary as much as 6 times, indi-
cating that for a given specific energy, the biological res-
ponses can also vary 6 times or more (SF in (2)).
3.4. Radioisotopes. The clinical application of TAT is focused
on alpha particle emitters of 211At, 213Bi, 223Ra, and 225Ac
[40–42]. The physical properties of these radionuclides,
including half-life, mean particle energy, maximum particle
energy, and average range in tissue, affect the therapeutic
result and are listed in Table 2 [43, 44].
For an AIC with a long residence time in a tumor, a radio-
nuclide with a long half-life will deliver more decays than one
with a short half-life (t1/2) for the same initial radioactivity
[44]. The number of radionuclides (N) to produce activity
(A) is
N = A
λ
= A
(0.693/t1/2)
. (4)
For TAT aimed at destroying all cancer cells in the tumor,
deep penetration and uniform distribution of the AIC would
be crucial. Thus, the longer half-life radioisotope would be a
better choice. However, if the aim is to destroy tumor capil-
laries, poor AIC diffusion away from the capillaries and
shorter half-life would be an advantage [19].
The longer half-life of 225Ac and the 4 alpha particle emis-
sions (Figure 2) gives greater toxicity and can prolong
survival in the mouse xenograft models for several cancers
[45]. However, the drawback is that the binding energy of
the chelation is not strong enough to withstand the alpha
particle recoil energy of the Actinium ion (between 100 and
200 keV). Daughters of 225Ac will lose tumor selectivity and
could diffuse away, causing cell damage in normal tissue
[16, 46].
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Table 2: Physical properties of alpha-particle emitters.
Radionuclide Z Half-life Mean particle energy∗ (MeV) Maximum energy (MeV) Average range (μm) <LET> (keV/μm)
211At 85 7.2 h 6.79 7.45 60 71
213Bi 83 45.6 min 8.32 8.38 84 61
223Ra 88 11.43 d 5.64 7.59 45 81
225Ac 89 10.0 d 6.83 8.38 61 71
∗weighted average of emissions.
229Th
7.34E3 y
225Ra
14.8 d
α
α
α
α
α
β
β
ββ
225Ac
10 d
221Fr
4.8 m
217At
32.3 ms
213Bi
45.6 m (97.84%)
209Tl
2.2 m
213Po
4.2 μs
209Pb
3.253 h
209Bi
Stable
α (2.16%)
Figure 2: The decay chain of 225Ac and 213Bi.
3.5. Biological Factors. There are great complexities of the
mammalian cell, the nucleus and its internal structures and
pathways, types of DNA damage, and cellular repair. For
cancer-cell cluster or solid-tumor modeling, a precise kinetic
description of AICs diffusing through cells and saturating
antigenic sites is needed for microdosimetry. The number of
AICs in the solid tumor depends critically on the capillary
permeability and the number of antigens expressed on cells
that can vary 10-fold and more. As such, the calculations rest
on realistic assumptions but results, in spite of the quanti-
tative nature of the Monte Carlo calculation, are qualitative
only.
4. Conclusion
Targeted Alpha Therapy uses radio-isotopes that emit alpha
radiation to kill targeted cancer cells. It is most effective in the
elimination of single-cancer cells and micrometastases before
the tumors grow to become clinically evident. The applica-
tion has been extended to the treatment of solid tumors by
tumor antivascular alpha therapy. Because the short range
of alpha particles is comparable to the size of the biological
target and the variable distribution of alpha emitters, stocha-
stic processes apply, and Monte Carlo calculations of micro-
dosimetry are indispensible in the investigation of biological
response mechanisms.
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